Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabinoid nasal spray micelle for chemotherapy-induced nausea and vomiting
ACTRN12615000414516Phase 2Withdrawn
- Sponsor
- The University of Sydney
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing CBD nasal spray + standard antiemetics with Placebo nasal spray + standard antiemetics (2 arms). Primary endpoint: Complete response. Planned start Feb 2016; status: withdrawn.
02
Drugs
cannabidiol
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ACTRN12615000414516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000414516.